AIM: Development of a sensitive method for DNA methylation profiling and associated mutation detection in clinical samples. MATERIALS & METHODS: Formalin-fixed and paraffin-embedded tumors received by clinical laboratories often contain insufficient DNA for analysis with bisulfite or methylation sensitive restriction enzymes-based methods. To increase sensitivity, methyl-CpG DNA capture and Coupled Abscription PCR Signaling detection were combined in a new assay, MethylMeter(®). Gliomas were analyzed for MGMT methylation, glioma CpG island methylator phenotype and IDH1 R132H. RESULTS: MethylMeter had 100% assay success rate measuring all five biomarkers in formalin-fixed and paraffin-embedded tissue. MGMT methylation results were supported by survival and mRNA expression data. CONCLUSION: MethylMeter is a sensitive and quantitative method for multitarget DNA methylation profiling and associated mutation detection. The MethylMeter-based GliomaSTRAT assay measures methylation of four targets and one mutation to simultaneously grade gliomas and predict their response to temozolomide. This information is clinically valuable in management of gliomas.
AIM: Development of a sensitive method for DNA methylation profiling and associated mutation detection in clinical samples. MATERIALS & METHODS:Formalin-fixed and paraffin-embedded tumors received by clinical laboratories often contain insufficient DNA for analysis with bisulfite or methylation sensitive restriction enzymes-based methods. To increase sensitivity, methyl-CpG DNA capture and Coupled Abscription PCR Signaling detection were combined in a new assay, MethylMeter(®). Gliomas were analyzed for MGMT methylation, glioma CpG island methylator phenotype and IDH1 R132H. RESULTS: MethylMeter had 100% assay success rate measuring all five biomarkers in formalin-fixed and paraffin-embedded tissue. MGMT methylation results were supported by survival and mRNA expression data. CONCLUSION: MethylMeter is a sensitive and quantitative method for multitarget DNA methylation profiling and associated mutation detection. The MethylMeter-based GliomaSTRAT assay measures methylation of four targets and one mutation to simultaneously grade gliomas and predict their response to temozolomide. This information is clinically valuable in management of gliomas.
Entities:
Keywords:
CIMP; DNA methylation; IDH1 mutation; MGMT; brain cancer; glioma
Authors: Robert J Klose; Shireen A Sarraf; Lars Schmiedeberg; Suzanne M McDermott; Irina Stancheva; Adrian P Bird Journal: Mol Cell Date: 2005-09-02 Impact factor: 17.970
Authors: Mathias Ehrich; Matthew R Nelson; Patrick Stanssens; Marc Zabeau; Triantafillos Liloglou; George Xinarianos; Charles R Cantor; John K Field; Dirk van den Boom Journal: Proc Natl Acad Sci U S A Date: 2005-10-21 Impact factor: 11.205
Authors: E H van Beers; S A Joosse; M J Ligtenberg; R Fles; F B L Hogervorst; S Verhoef; P M Nederlof Journal: Br J Cancer Date: 2006-01-30 Impact factor: 7.640
Authors: Neha Singh; Varune R Ramnarine; Jin H Song; Ritu Pandey; Sathish K R Padi; Mannan Nouri; Virginie Olive; Maxim Kobelev; Koichi Okumura; David McCarthy; Michelle M Hanna; Piali Mukherjee; Belinda Sun; Benjamin R Lee; J Brandon Parker; Debabrata Chakravarti; Noel A Warfel; Muhan Zhou; Jeremiah J Bearss; Ewan A Gibb; Mohammed Alshalalfa; R Jefferey Karnes; Eric J Small; Rahul Aggarwal; Felix Feng; Yuzhuo Wang; Ralph Buttyan; Amina Zoubeidi; Mark Rubin; Martin Gleave; Frank J Slack; Elai Davicioni; Himisha Beltran; Colin Collins; Andrew S Kraft Journal: Nat Commun Date: 2021-12-21 Impact factor: 17.694